相关实验视频
Updated: Feb 19, 2026
10:42
A Tripeptide-Stabilized Nanoemulsion of Oleic Acid
Published on: February 27, 2019
9.9K
一种多域-脂质体复合物,用于口腔癌中循环二核酸的受控释放
Joseph W R Swain1, Andrea H Molina2, Gemalene M Sunga2
1Department of Chemistry, Rice University, 6100 Main Street, Houston, TX 77098, USA.
概括
一种新型的基脂酶体系统,K2-Lip ((CDN),延长了循环二核酸 (CDN) 的可用性,用于头部和部状细胞癌 (HNSCC) 治疗,单剂量显著提高了存活率.
科学领域:
- 生物材料科学 生物材料科学
- 癌症研究 癌症研究
- 免疫治疗是一种免疫疗法.
背景情况:
- 免疫疗法是一种有前途的癌症治疗方法,但许多头部和部状细胞癌 (HNSCC) 患者对单剂治疗没有反应.
- 循环二核酸 (CDN) 是STING激动剂,可以增强抗瘤反应,但需要经常服用.
研究的目的:
- 开发一种新型药物输送系统,以延长CDN的本地可用性,以减少药物输送的频率.
- 在临床前的HNSCC模型中研究基-脂质体复合系统 (K2-Lip(CDN)) 的疗效.
主要方法:
- 创建了一个K2-Lip ((CDN) 复合系统,使用阴离子水凝和体封装CDN.
- 研究了水凝的特性,体外的CDN释放动力学,体内的绿色氨酸 (ICG) 释放.
- 在试验室使用ROC1口腔癌细胞和在ROC1瘤携带的小鼠模型中体内评估K2-Lip ((CDN) 的疗效.
主要成果:
- K2-Lip (CDN) 系统表现出自我愈合特性和CDN和ICG的长时间释放.
- 单剂量K2-Lip (CDN) 在体外显示显著的细胞毒性,在体内延长生存时间.
- 一次剂量K2-Lip (CDN) 的生存结果与六次重复剂量的自由CDN相比.
结论:
- 酸液凝-脂质体复合系统为局部,持续的药物输送提供了一个有希望的策略.
- K2-Lip ((CDN) 有效地减少了用于HNSCC治疗的CDN所需的注射频率.
- 这项技术具有广泛应用的潜力,需要延迟释放局部治疗药物.
相关概念视频
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
31
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
31
01:11Oral Drug Delivery Systems: Delayed-Release Systems
39
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
39
01:24Modified-Release Drug Delivery Systems: Site-Targeted
25
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
25